MCID: GLS001
MIFTS: 58

Gliosarcoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Gliosarcoma

MalaCards integrated aliases for Gliosarcoma:

Name: Gliosarcoma 12 76 53 59 55 44 15 73
Glioblastoma with Sarcomatous Component 12
Sarcomatous Glioblastoma 53

Characteristics:

Orphanet epidemiological data:

59
gliosarcoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3071
MeSH 44 D018316
NCIt 50 C3796
Orphanet 59 ORPHA251576
ICD10 via Orphanet 34 G71.9
UMLS via Orphanet 74 C0206726
UMLS 73 C0206726

Summaries for Gliosarcoma

MalaCards based summary : Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to glioma susceptibility 1 and anaplastic ganglioglioma, and has symptoms including headache and seizures. An important gene associated with Gliosarcoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Carmustine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and bone, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 76 Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...

Related Diseases for Gliosarcoma

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 31.3 IDH1 PPARG TP53
2 anaplastic ganglioglioma 31.2 GFAP NES
3 ganglioglioma 31.1 GFAP NES TP53
4 teratoma 31.0 GFAP NES TP53
5 ependymoma 30.9 EGFR GFAP MGMT NES RB1
6 fibrillary astrocytoma 30.8 GFAP IDH1 MGMT TP53
7 grade iii astrocytoma 30.7 EGFR GFAP MGMT PTEN TP53
8 li-fraumeni syndrome 30.2 EGFR IDH1 PTEN TP53
9 oligodendroglioma 30.1 EGFR GFAP IDH1 MGMT PTEN TP53
10 glioblastoma 30.1 EGFR FGFR1 IDH1 MGMT PPARG PTEN
11 squamous cell carcinoma 30.0 EGFR FGFR3 PTEN RB1 TP53
12 glioma 29.9 EGFR FGFR1 IDH1 PPARG PTEN TP53
13 pilocytic astrocytoma 29.8 FGFR1 GFAP IDH1 MGMT PTEN TP53
14 glioblastoma multiforme 29.7 EGFR GFAP IDH1 MGMT NES PPARG
15 medulloblastoma 29.5 EGFR FGFR1 GFAP IDH1 MGMT NES
16 giant cell glioblastoma 26.6 EGFR FGFR1 FGFR3 GFAP IDH1 LZTR1
17 adult brainstem gliosarcoma 12.0
18 frontal convexity meningioma 11.2 GFAP TP53
19 vulvar adenocarcinoma 11.2 RB1 TP53
20 gliofibroma 11.2 GFAP TP53
21 oligoastrocytoma 11.2 GFAP MGMT
22 central nervous system teratoma 11.2 GFAP NES
23 central nervous system primitive neuroectodermal neoplasm 11.1 GFAP NES TP53
24 ependymoblastoma 11.1 GFAP NES TP53
25 brain ependymoma 11.1 EGFR TP53
26 retinal cancer 11.1 CCND3 RB1 TP53
27 optic nerve glioma 11.1 GFAP NES TP53
28 sensory system cancer 11.1 CCND3 RB1 TP53
29 infratentorial cancer 11.1 GFAP NES TP53
30 cerebral convexity meningioma 11.1 GFAP TP53
31 protoplasmic astrocytoma 11.1 GFAP TP53
32 ocular cancer 11.1 CCND3 RB1 TP53
33 anaplastic oligodendroglioma 11.0 EGFR GFAP MGMT
34 cellular ependymoma 11.0 GFAP TP53
35 extraventricular neurocytoma 11.0 GFAP IDH1
36 mixed glioma 11.0 GFAP IDH1 TP53
37 intracranial chondrosarcoma 10.9 IDH1 TP53
38 splenic diffuse red pulp small b-cell lymphoma 10.9 CCND3 TP53
39 adult medulloblastoma 10.9 GFAP IDH1 TP53
40 dysembryoplastic neuroepithelial tumor 10.9 GFAP IDH1 NES
41 cerebellar astrocytoma 10.9 IDH1 TP53
42 breast carcinoma in situ 10.9 EGFR FGFR1 TP53
43 pleomorphic xanthoastrocytoma 10.9 GFAP IDH1 MGMT TP53
44 spinal cord astrocytoma 10.9 GFAP IDH1 MGMT TP53
45 adult oligodendroglioma 10.9 FGFR1 IDH1
46 plagiocephaly 10.8 FGFR1 FGFR3
47 renal hypodysplasia/aplasia 3 10.8 FGFR3 FREM2
48 non-invasive bladder papillary urothelial neoplasm 10.8 FGFR3 TP53
49 osteochondroma 10.8 FGFR1 FGFR3 NES
50 brain glioma 10.8 EGFR GFAP MGMT NES TP53

Graphical network of the top 20 diseases related to Gliosarcoma:



Diseases related to Gliosarcoma

Symptoms & Phenotypes for Gliosarcoma

UMLS symptoms related to Gliosarcoma:


headache, seizures

MGI Mouse Phenotypes related to Gliosarcoma:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 FGFR1 EGFR CCND3 GFAP IDH1 FREM2
2 homeostasis/metabolism MP:0005376 10.4 TP53 CCND3 FGFR1 EGFR GFAP FGFR3
3 mortality/aging MP:0010768 10.4 FGFR1 EGFR CCND3 IDH1 FREM2 LZTR1
4 hematopoietic system MP:0005397 10.38 FGFR1 EGFR CCND3 IDH1 LZTR1 FGFR3
5 immune system MP:0005387 10.36 FGFR1 EGFR CCND3 GFAP IDH1 FGFR3
6 endocrine/exocrine gland MP:0005379 10.33 CCND3 FGFR1 EGFR MGMT NFKBIA PTEN
7 cardiovascular system MP:0005385 10.32 TP53 CCND3 FGFR1 EGFR GFAP FREM2
8 embryo MP:0005380 10.25 TP53 FGFR1 EGFR FREM2 PPARG PTEN
9 integument MP:0010771 10.24 FGFR1 EGFR FGFR3 FREM2 NFKBIA PTEN
10 craniofacial MP:0005382 10.21 TP53 FGFR1 EGFR FGFR3 FREM2 SNAI2
11 digestive/alimentary MP:0005381 10.21 TP53 FGFR1 EGFR GFAP FGFR3 PTEN
12 normal MP:0002873 10.14 FGFR1 EGFR CCND3 FGFR3 GFAP RB1
13 limbs/digits/tail MP:0005371 10.13 TP53 FGFR1 EGFR FGFR3 FREM2 PTEN
14 hearing/vestibular/ear MP:0005377 10.12 TP53 FGFR1 EGFR FGFR3 FREM2 PPARG
15 neoplasm MP:0002006 10.11 EGFR CCND3 MGMT FGFR3 RB1 PTEN
16 muscle MP:0005369 10.08 TP53 FGFR1 EGFR GFAP FREM2 PPARG
17 liver/biliary system MP:0005370 10.05 TP53 CCND3 EGFR PPARG PTEN TACC3
18 no phenotypic analysis MP:0003012 9.98 TP53 FGFR1 EGFR FGFR3 PPARG MGMT
19 renal/urinary system MP:0005367 9.92 TP53 FGFR1 EGFR FGFR3 FREM2 PTEN
20 reproductive system MP:0005389 9.91 TP53 FGFR1 EGFR FGFR3 FREM2 PPARG
21 pigmentation MP:0001186 9.85 TP53 EGFR FREM2 PTEN SNAI2 RB1
22 respiratory system MP:0005388 9.81 CCND3 EGFR FGFR3 IDH1 FREM2 MGMT
23 skeleton MP:0005390 9.7 FGFR1 EGFR IDH1 FREM2 FGFR3 PTEN
24 vision/eye MP:0005391 9.36 FGFR1 EGFR CCND3 FREM2 FGFR3 GFAP

Drugs & Therapeutics for Gliosarcoma

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 398)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
2
Lomustine Approved, Investigational Phase 3,Phase 1 13010-47-4 3950
3
Procarbazine Approved, Investigational Phase 3,Phase 1,Phase 2 671-16-9 4915
4
Trioxsalen Approved Phase 3,Phase 1 3902-71-4 5585
5
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
6
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
10
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
13
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
14
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
15
Dopamine Approved Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
16
Cyproheptadine Approved Phase 3 129-03-3 2913
17
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
18
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
19 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
20
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
21 Dianhydrogalactitol Investigational Phase 3 23261-20-3
22 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
25 Dihematoporphyrin Ether Phase 3,Phase 1
26 Ether Phase 3
27 Photosensitizing Agents Phase 3,Phase 2,Phase 1
28 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
29 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antibodies Phase 3,Phase 1,Phase 2,Early Phase 1
31 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2,Early Phase 1
32 Immunoglobulins Phase 3,Phase 1,Phase 2,Early Phase 1
33 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Not Applicable
34 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
35 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
36 Antimitotic Agents Phase 3,Phase 1,Phase 2
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
38 Keratolytic Agents Phase 3,Phase 1,Phase 2
39 O(6)-benzylguanine Phase 3,Phase 2,Phase 1,Not Applicable
40 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
41 Immunoglobulin G Phase 3,Phase 1,Phase 2
42 Mitogens Phase 3,Phase 1,Phase 2
43 Anesthetics Phase 3,Phase 1
44 Anesthetics, General Phase 3
45 Anesthetics, Inhalation Phase 3
46 Hematoporphyrin Derivative Phase 3
47 Hematoporphyrins Phase 3
48 Adjuvants, Anesthesia Phase 3
49 Analgesics Phase 3,Phase 2,Phase 1
50 Analgesics, Opioid Phase 3

Interventional clinical trials:

(show top 50) (show all 471)
# Name Status NCT ID Phase Drugs
1 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
3 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
4 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
5 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
6 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
7 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
8 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
9 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
10 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
11 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
12 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
13 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
16 A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification ( Intellance1 ) Recruiting NCT02573324 Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
17 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Active, not recruiting NCT02152982 Phase 2, Phase 3 Temozolomide;Veliparib
18 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Active, not recruiting NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
21 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
22 Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Unknown status NCT01124539 Phase 2 AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
23 Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 Unknown status NCT02430363 Phase 1, Phase 2 MK - 3475
24 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Unknown status NCT01013285 Phase 2 temozolomide
25 Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma Unknown status NCT00936052 Phase 2
26 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
27 Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00486603 Phase 1, Phase 2 hydroxychloroquine;temozolomide
28 Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
29 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
30 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
31 Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
32 Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
33 Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
34 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
35 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
36 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma Completed NCT00525525 Phase 2 Bevacizumab;Tarceva;Temozolomide
37 Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas Completed NCT00612339 Phase 2 Avastin and Temozolomide
38 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
39 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed NCT00597402 Phase 2 Avastin;Temozolomide;Irinotecan
40 Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed NCT00402116 Phase 1, Phase 2 enzastaurin;temozolomide
41 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors Completed NCT00187486 Phase 2 Tarceva;Temodar
42 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed NCT00433381 Phase 2 irinotecan hydrochloride;temozolomide
43 Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00305864 Phase 1, Phase 2 Motexafin Gadolinium;Temozolomide
44 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Completed NCT00979017 Phase 2 Avastin;Temozolomide;Irinotecan
45 Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00165477 Phase 2 lenalidomide
46 Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Completed NCT00883298 Phase 2 temozolomide and bevacizumab
47 AMG 102 and Avastin for Recurrent Malignant Glioma Completed NCT01113398 Phase 2 AMG 102;Avastin
48 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma Completed NCT00028795 Phase 2 temozolomide
49 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Completed NCT01856933 Phase 2 PSMA ADC
50 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea

Search NIH Clinical Center for Gliosarcoma

Cochrane evidence based reviews: gliosarcoma

Genetic Tests for Gliosarcoma

Anatomical Context for Gliosarcoma

MalaCards organs/tissues related to Gliosarcoma:

41
Brain, T Cells, Bone, Bone Marrow, Prostate, Liver, Spinal Cord

Publications for Gliosarcoma

Articles related to Gliosarcoma:

(show top 50) (show all 374)
# Title Authors Year
1
Gliosarcoma: a clinical and radiological analysis of 48 cases. ( 29948068 )
2018
2
Treatment-associated<i>TP53</i>DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma. ( 29416795 )
2018
3
Adjuvant Radiation Therapy and Temozolomide in Gliosarcoma: Is It Enough? Case Series of Seven Patients. ( 29682024 )
2018
4
Giant parieto-occipital lobe pediatric gliosarcoma: Report of a rare entity and review of literature. ( 29930877 )
2018
5
Pineal gliosarcoma in a 5-year-old girl. ( 29487662 )
2018
6
Gliosarcoma with primitive neuronal, chondroid, osteoid and ependymal elements. ( 29504169 )
2018
7
Photodithazine photodynamic effect on viability of 9L/lacZ gliosarcoma cell line. ( 28503718 )
2017
8
Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24h in a rat 9L gliosarcoma model. ( 28887206 )
2017
9
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. ( 28812310 )
2017
10
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. ( 28261869 )
2017
11
Lateral ventricular gliosarcoma with attachment to septum pellucidum. ( 28413542 )
2017
12
Gliosarcomas with the BRAF V600E mutation: a report of two cases and review of the literature. ( 28775171 )
2017
13
Glioblastoma recurrence, progression, and dissemination as a purely subdural gliosarcoma. ( 28290000 )
2017
14
Analysis of outcomes of multidisciplinary management of Gliosarcoma: a single centre study, 2000-2013. ( 28642179 )
2017
15
Detailed magnetic resonance imaging features of a case series of primary gliosarcoma. ( 28644110 )
2017
16
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients? ( 29045711 )
2017
17
Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. ( 28621623 )
2017
18
Primary gliosarcoma: epidemiology, clinical presentation, management and survival. ( 29154508 )
2017
19
Gliosarcoma in septuagenarians and octogenarians: What is the impact of adjuvant chemoradiation? ( 28756069 )
2017
20
Functional and morphological effects of diazepam and midazolam on tumor vasculature in the 9L gliosarcoma brain tumor model using dynamic susceptibility contrast MRI: a comparative study. ( 29042753 )
2017
21
Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. ( 29264835 )
2017
22
Gliosarcoma in Young Adults: A Rare Variant of Glioblastoma. ( 29147435 )
2017
23
High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. ( 28408749 )
2017
24
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
25
Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. ( 26725096 )
2016
26
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. ( 27169763 )
2016
27
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )
2016
28
An IDH1-mutated primary gliosarcoma: case report. ( 27153165 )
2016
29
Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging. ( 26802746 )
2016
30
Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( 27025857 )
2016
31
Dural and osteolytic sarcomatoid relapse of a secondary gliosarcoma with tryptase immunoreactivity. ( 26784965 )
2016
32
A Stable Secondary Gliosarcoma with Extensive Systemic Metastases: A Case Report. ( 27867925 )
2016
33
Temporal Lobe Gliosarcoma After Gamma Knife Radiosurgery for Vestibular Schwannoma. ( 27309712 )
2016
34
Gliosarcoma with Primary Skull Base Invasion. ( 28053799 )
2016
35
Gliosarcoma with a primitive neuroectodermal tumour component. ( 27772848 )
2016
36
Metastatic Gliosarcoma: Cytopathologic Characteristics with Histopathologic Correlations. ( 27584833 )
2016
37
Gliosarcoma with smooth muscle cell differentiation: a case report. ( 27704522 )
2016
38
Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature. ( 27672648 )
2016
39
Primary Multifocal Gliosarcoma of the Spinal Cord. ( 27134708 )
2016
40
Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma. ( 27130721 )
2016
41
Gliosarcomas lack BRAF(V600E) mutation, but a subset exhibit I^-catenin nuclear localization. ( 26932501 )
2016
42
Gliosarcoma in the Cerebellopontine Angle with Rapid Tumor Growth and Intratumoral Hemorrhage. ( 27338213 )
2016
43
Concurrent Gliosarcoma and Choroid Plexus Carcinoma in a Cow. ( 27899174 )
2016
44
Post-Treatment Gliosarcoma Extension into the Pterygomaxillary Fossa: Literature Review and Case Report. ( 27699141 )
2016
45
Primary Gliosarcoma of the Optic Nerve: A Unique Adult Optic Pathway Glioma. ( 27792048 )
2016
46
Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient. ( 27523101 )
2016
47
Assessing Amide Proton Transfer (APT) MRI Contrast Origins in 9A L Gliosarcoma in the Rat Brain Using Proteomic Analysis. ( 25622812 )
2015
48
Primary Cerebellar Gliosarcoma with Extracranial Metastases: An Orphan Differential Diagnosis. ( 26239018 )
2015
49
Gliosarcoma with neuroaxis metastases. ( 26621904 )
2015
50
Long-term survival in gliosarcoma with radiation-induced meningeal sarcomas: Case report and molecular features. ( 26458625 )
2015

Variations for Gliosarcoma

Cosmic variations for Gliosarcoma:

9
(show top 50) (show all 75)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10704 TP53 central nervous system,brain,glioma,gliosarcoma c.844C>T p.R282W 17:7673776-7673776 6
2 COSM10656 TP53 central nervous system,brain,glioma,gliosarcoma c.742C>T p.R248W 17:7674221-7674221 6
3 COSM10893 TP53 central nervous system,brain,glioma,gliosarcoma c.824G>A p.C275Y 17:7673796-7673796 6
4 COSM10648 TP53 central nervous system,brain,glioma,gliosarcoma c.524G>A p.R175H 17:7675088-7675088 6
5 COSM11244 TP53 central nervous system,brain,glioma,gliosarcoma c.764T>A p.I255N 17:7674199-7674199 6
6 COSM44171 TP53 central nervous system,brain,glioma,gliosarcoma c.840A>T p.R280S 17:7673780-7673780 6
7 COSM10742 TP53 central nervous system,brain,glioma,gliosarcoma c.578A>G p.H193R 17:7674953-7674953 6
8 COSM6914505 STAG2 central nervous system,brain,glioma,gliosarcoma c.953T>G p.M318R 23:124050245-124050245 6
9 COSM6914502 SMAD3 central nervous system,brain,glioma,gliosarcoma c.686C>T p.P229L 15:67181268-67181268 6
10 COSM6914501 RB1 central nervous system,brain,glioma,gliosarcoma c.446C>A p.S149* 13:48345145-48345145 6
11 COSM866 RB1 central nervous system,brain,glioma,gliosarcoma c.1399C>T p.R467* 13:48380062-48380062 6
12 COSM24612 PTPN11 central nervous system,brain,glioma,gliosarcoma c.922A>G p.N308D 12:112477719-112477719 6
13 COSM5089 PTEN central nervous system,brain,glioma,gliosarcoma c.517C>T p.R173C 10:87952142-87952142 6
14 COSM13731 PTEN central nervous system,brain,glioma,gliosarcoma c.802-2A>T p.? 10:87960892-87960892 6
15 COSM5154 PTEN central nervous system,brain,glioma,gliosarcoma c.697C>T p.R233* 10:87957915-87957915 6
16 COSM5191 PTEN central nervous system,brain,glioma,gliosarcoma c.198G>T p.K66N 10:87925546-87925546 6
17 COSM5152 PTEN central nervous system,brain,glioma,gliosarcoma c.388C>T p.R130* 10:87933147-87933147 6
18 COSM6954363 PTEN central nervous system,brain,glioma,gliosarcoma c.688G>T p.G230* 10:87957906-87957906 6
19 COSM5033 PTEN central nervous system,brain,glioma,gliosarcoma c.389G>A p.R130Q 10:87933148-87933148 6
20 COSM5123 PTEN central nervous system,brain,glioma,gliosarcoma c.395G>A p.G132D 10:87933154-87933154 6
21 COSM6955728 PTEN central nervous system,brain,glioma,gliosarcoma c.686C>A p.S229* 10:87957904-87957904 6
22 COSM5162 PTEN central nervous system,brain,glioma,gliosarcoma c.821G>A p.W274* 10:87960913-87960913 6
23 COSM5308 PTEN central nervous system,brain,glioma,gliosarcoma c.565A>T p.R189* 10:87952190-87952190 6
24 COSM775 PIK3CA central nervous system,brain,glioma,gliosarcoma c.3140A>G p.H1047R 3:179234297-179234297 6
25 COSM22413 PDGFRA central nervous system,brain,glioma,gliosarcoma c.2472C>T p.V824V 4:54285873-54285873 6
26 COSM564 NRAS central nervous system,brain,glioma,gliosarcoma c.35G>A p.G12D 1:114716126-114716126 6
27 COSM41793 NF1 central nervous system,brain,glioma,gliosarcoma c.7765C>T p.Q2589* 17:31356986-31356986 6
28 COSM510736 NF1 central nervous system,brain,glioma,gliosarcoma c.7909C>T p.R2637* 17:31357308-31357308 6
29 COSM6920964 MSH6 central nervous system,brain,glioma,gliosarcoma c.3397A>G p.T1133A 2:47803644-47803644 6
30 COSM6954365 MED12 central nervous system,brain,glioma,gliosarcoma c.2345T>C p.L782P 23:71125469-71125469 6
31 COSM6978572 KDR central nervous system,brain,glioma,gliosarcoma c.2498G>A p.R833Q 4:55098148-55098148 6
32 COSM22932 FBXW7 central nervous system,brain,glioma,gliosarcoma c.1393C>T p.R465C 4:152328233-152328233 6
33 COSM6920966 FAT1 central nervous system,brain,glioma,gliosarcoma c.9056A>G p.N3019S 4:186617024-186617024 6
34 COSM6920965 FAT1 central nervous system,brain,glioma,gliosarcoma c.9056A>G p.N3019S 4:186617024-186617024 6
35 COSM6911771 EED central nervous system,brain,glioma,gliosarcoma c.455G>A p.W152* 11:86256415-86256415 6
36 COSM476 BRAF central nervous system,brain,glioma,gliosarcoma c.1799T>A p.V600E 7:140753336-140753336 6
37 COSM453 BRAF central nervous system,brain,glioma,gliosarcoma c.1397G>A p.G466E 7:140781611-140781611 6
38 COSM471 BRAF central nervous system,brain,glioma,gliosarcoma c.1790T>G p.L597R 7:140753345-140753345 6
39 COSM1587098 central nervous system,brain,glioma,gliosarcoma c.1399C>T p.R467* 13:48380062-48380062 6
40 COSM1740322 central nervous system,brain,glioma,gliosarcoma c.578A>G p.H193R 17:7674953-7674953 6
41 COSM6954366 central nervous system,brain,glioma,gliosarcoma c.2345T>C p.L782P 23:71125469-71125469 6
42 COSM3388181 central nervous system,brain,glioma,gliosarcoma c.764T>A p.I255N 17:7674199-7674199 6
43 COSM1382232 central nervous system,brain,glioma,gliosarcoma c.7909C>T p.R2637* 17:31357308-31357308 6
44 COSM308307 central nervous system,brain,glioma,gliosarcoma c.578A>G p.H193R 17:7674953-7674953 6
45 COSM1154293 central nervous system,brain,glioma,gliosarcoma c.1039C>T p.R347C 4:152328233-152328233 6
46 COSM2744526 central nervous system,brain,glioma,gliosarcoma c.840A>T p.R280S 17:7673780-7673780 6
47 COSM170725 central nervous system,brain,glioma,gliosarcoma c.1153C>T p.R385C 4:152328233-152328233 6
48 COSM6920967 central nervous system,brain,glioma,gliosarcoma c.7765C>T p.Q2589* 17:31356986-31356986 6
49 COSM94986 central nervous system,brain,glioma,gliosarcoma c.3140A>G p.H1047R 3:179234297-179234297 6
50 COSM3378339 central nervous system,brain,glioma,gliosarcoma c.844C>T p.R282W 17:7673776-7673776 6

Expression for Gliosarcoma

Search GEO for disease gene expression data for Gliosarcoma.

Pathways for Gliosarcoma

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 CCND3 EGFR FGFR1 FGFR3 GFAP NFKBIA
2
Show member pathways
12.85 CCND3 EGFR FGFR1 FGFR3 PTEN RB1
3
Show member pathways
12.72 EGFR FGFR1 PTEN RB1 TP53
4
Show member pathways
12.69 EGFR FGFR1 FGFR3 PTEN RB1 TP53
5
Show member pathways
12.69 EGFR FGFR1 NFKBIA PPARG PTEN RB1
6
Show member pathways
12.63 EGFR FGFR1 FGFR3 NFKBIA PTEN TP53
7 12.46 CCND3 MGMT RB1 TACC3 TP53
8
Show member pathways
12.44 EGFR FGFR1 FGFR3 PTEN TP53
9
Show member pathways
12.38 EGFR FGFR1 FGFR3 NFKBIA TP53
10 12.37 CCND3 NFKBIA RB1 TP53
11
Show member pathways
12.33 CCND3 PTEN RB1 TP53
12 12.33 CCND3 EGFR FGFR1 FGFR3 NFKBIA PPARG
13 12.25 CCND3 NFKBIA RB1 TP53
14
Show member pathways
12.19 EGFR FGFR1 FGFR3 PTEN
15 12.13 CCND3 PTEN RB1 TP53
16 12.1 EGFR PTEN RB1 TP53
17 12.05 EGFR FGFR1 FGFR3 PTEN TP53
18
Show member pathways
11.99 CCND3 NFKBIA PTEN TP53
19 11.95 EGFR GFAP RB1 TP53
20 11.89 EGFR PTEN RB1 SNAI2 TP53
21 11.85 FGFR1 FGFR3 GFAP SNAI2
22 11.8 EGFR PTEN RB1
23 11.79 CCND3 RB1 TP53
24 11.79 NFKBIA PTEN RB1 TP53
25 11.76 EGFR MGMT PTEN RB1 TP53
26
Show member pathways
11.74 CCND3 EGFR FGFR1 FGFR3 RB1
27 11.68 EGFR FGFR1 SNAI2
28 11.66 FGFR1 FGFR3 GFAP NES
29 11.6 EGFR FGFR3 RB1 TP53
30 11.52 EGFR RB1 TP53
31 11.46 PTEN RB1 TP53
32 11.45 EGFR FGFR1 FGFR3
33 11.42 CCND3 NFKBIA TP53
34 11.4 EGFR FGFR1 FGFR3
35 11.05 NFKBIA TACC1 TACC3 TP53
36 10.91 EGFR FGFR1 FGFR3 IDH1 PTEN TP53

GO Terms for Gliosarcoma

Cellular components related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1
2 PML body GO:0016605 9.13 PTEN RB1 TP53

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.93 CCND3 FGFR1 PPARG RB1 SNAI2 TP53
2 multicellular organism development GO:0007275 9.86 EGFR FGFR1 FGFR3 FREM2 NES PPARG
3 regulation of cell proliferation GO:0042127 9.84 CCND3 EGFR FGFR1 NFKBIA
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 EGFR FGFR1 FGFR3 PTEN
5 cell division GO:0051301 9.8 CCND3 RB1 SEPT14 TACC1 TACC3
6 cell cycle GO:0007049 9.8 CCND3 RB1 SEPT14 TACC1 TACC3 TP53
7 cell proliferation GO:0008283 9.77 EGFR PTEN TACC1 TACC3 TP53
8 positive regulation of kinase activity GO:0033674 9.65 EGFR FGFR1 FGFR3
9 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.56 NFKBIA PPARG
10 white fat cell differentiation GO:0050872 9.55 PPARG SNAI2
11 negative regulation of telomerase activity GO:0051974 9.51 PPARG TP53
12 salivary gland morphogenesis GO:0007435 9.49 EGFR FGFR1
13 positive regulation of phospholipase activity GO:0010518 9.43 FGFR1 FGFR3
14 response to organic cyclic compound GO:0014070 9.35 EGFR IDH1 MGMT PPARG PTEN
15 cellular response to ionizing radiation GO:0071479 9.33 MGMT SNAI2 TP53
16 negative regulation of apoptotic process GO:0043066 9.23 EGFR FGFR1 FGFR3 MGMT NFKBIA PTEN

Molecular functions related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAP kinase kinase kinase activity GO:0004709 9.61 EGFR FGFR1 FGFR3
2 protein phosphatase binding GO:0019903 9.58 EGFR PPARG TP53
3 mitogen-activated protein kinase kinase binding GO:0031434 9.54 EGFR FGFR1 FGFR3
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR FGFR1 FGFR3
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 EGFR FGFR1 FGFR3
6 enzyme binding GO:0019899 9.43 EGFR NFKBIA PPARG PTEN RB1 TP53
7 identical protein binding GO:0042802 9.32 EGFR FGFR1 FGFR3 GFAP IDH1 NFKBIA
8 fibroblast growth factor-activated receptor activity GO:0005007 9.16 FGFR1 FGFR3

Sources for Gliosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....